Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on β-catenin protein dysregulation, but not k-ras mutation

Journal of Pathology

Volumn 197, Issue 1, 2002, Pages 128-135

  Wong, N A C S ^a,c   Morris, R G ^b   McCondochie, A ^a   Bader, S ^b   Jodrell, D I ^b   Harrison, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

catenin; 5 fluorouracil; Colorectal carcinoma; Cyclin D1; k ras mutation; Microsatellite instability

Indexed keywords

BETA CATENIN; CYCLIN D1; DNA; FLUOROURACIL; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL NUCLEUS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT FAILURE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BETA CATENIN; CELL DIVISION; COLORECTAL NEOPLASMS; CYCLIN D1; CYTOSKELETAL PROTEINS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0036240630     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1113     Document Type: Article

References (48)

1. Cell cycle regulators: Mechanisms and their role in aetiology, prognosis, and treatment of cancer
2. Amplification and expression of the human cyclin D gene in esophageal cancer
3. Amplification and over-expression of cyclin D1 in breast cancer detected by immunohistochemical staining
4. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas
5. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis
6. Expression of cyclins D1 and E in human colon adenocarcinomas
7. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma
8. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer
9. Amplification of cyclin genes in colorectal carcinomas
10. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors
11. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster
12. Cyclin D1 expression is regulated by the retinoblastoma protein
13. Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa
14. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity
15. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes
16. Reciprocity between membranous and nuclear expression of β-catenin in colorectal tumours
17. β-Catenin signaling and cancer
18. Ras oncogenes in human colon cancer: A review
19. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
20. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
21. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway
22. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: Effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1
23. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression
24. Tumour markers of prognosis in colorectal cancer
25. 5-Fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer
26. Assessment of response to therapy in advanced breast cancer
27. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia
28. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique
29. Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer
30. Colorectal cancer with and without microsatellite instability involves different genes
31. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways
32. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency
33. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas
34. Epithelial tumors and tumor-like conditions
35. Expression of cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis
36. DNA mismatch repair and colorectal cancer
37. Colorectal cancer in idiopathic inflammatory bowel disease
38. Expression of E-cadherin-associated molecules (α-β- and γ-catenins and p120) in colorectal polyps
39. Expression of the cyclin D1 gene in rat colorectal aberrant crypt foci and tumors induced by azoxymethane
40. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis
41. Increased expression and nuclear β-catenin translocation accompany cellular hyperproliferation in vivo
42. β-Catenin expression in primary and metastatic colorectal carcinoma
43. Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity
44. p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis
45. β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer
46. Target genes of β-catenin-T cell factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas
47. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
48. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach